+44 20 8123 2220
info@marketpublishers.com

Global Antiretroviral Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

https://marketpublishers.com/r/G4B4DDE645DEN.html
Date: November 2017
Pages: 224
Price: US$ 4,400.00 (Single User License)
ID: G4B4DDE645DEN

Abstracts

Antiretroviral Drugs Market

Retroviruses is a single stranded RNA containing virus with DNA intermediate. Retrovirus use enzyme, reverse transcriptase to copy their RNA into DNA of the host cell. The retrovirus integrates its viral DNA into DNA of the host cell, which allows the retrovirus to replicate. Retroviruses can cause different outcomes for the infected cell. Retroviruses are capable of inducing autoimmune, immunosuppressive, and neurological illnesses. Some retroviruses, such as the spumaviruses and lentiviruses are capable of directly killing cells.

Cytopathic effects in cells in the brain and infected T cells may develop immune deficiencies and neurological diseases induced by HIV and related lentiviruses. Retrovirus causes immunological diseases including HIV and T-Cell leukaemia. Acquired immune deficiency syndrome (AIDS) caused by retrovirus known as human immunodeficiency virus (HIV) and T-Cell leukaemia caused by human T lymphotropic virus (HTLV). Antiretroviral drugs are the drugs that acts or inhibit certain process in viral replication and inhibits further worsening of the diseases.

Globally antiretroviral drugs market driven by increased cases of retroviral infections such as especially HIV/AIDS. According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS related illness in the same year. The higher prevalence of HIV owing to the various factors such as lack of availability of medication for the treatment of HIV infection, promising pipeline drugs, increased funding by the government are expected to bolster the antiretroviral drugs market over the forecast period. However, high costs of R&D and stringent regulatory

+44 20 8123 2220
info@marketpublishers.com

procedures hampering the antiretroviral drugs market. Furthermore, availability of the generic versions of blockbuster drugs affecting the market revenue of antiretroviral drugs.

Global antiretroviral drugs market is segmented based on drug class, route of administration, and distribution channel

Based on drug class, antiretroviral drugs are classified into

Nucleoside Reverse Transcriptase Inhibitors (NRT's)

Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)

Protease Inhibitors

Integrate Inhibitors

Fusion Inhibitors

Chemokine Receptor Inhibitors

Others

Based on route of administration, antiretroviral drugs are classified into

Oral

Parenteral

Based on distribution channel, antiretroviral drugs market is classified into

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

+44 20 8123 2220
info@marketpublishers.com

Others

Antiretroviral drugs market is expected to grow at significant rates during forecasting period owing to pipeline drugs such as doravirine (Merck & Co.), fostemsavir (Bristol-Myers Squibb), rilpivirine (Tibotec) etc. Market players are adopting strategies like mergers and acquisitions to improve the market share. In December 2015, ViiV Healthcare purchased Bristol-Myers Squibb's late stage HIV R&D assets. Market players are also actively collaborating with government and non-government organizations to educate the people and increase awareness related to retroviral diseases. For instance, in September 2016, in an effort to eradicate and combat HIV/AIDS and hypertension in Africa, under U.S. Presidents Emergency Plan for Aids Relief (PEPFAR), United States partnered with AstraZeneca Plc in donating US$10 million to HIV/AIDS funding.

Geographically antiretroviral drugs market is segmented into five key regions Viz. North America, Europe, Asia- Pacific, Latin America, and Middle East & Africa. North America antiretroviral market is driven by introduction of combination therapies such as antiretroviral therapy dosages by key players in the region. Asia Pacific region expected to be fastest growing due to developing healthcare infrastructure and increase in government and non-government organization initiatives creating awareness of retroviral diseases especially HIV/AIDS. Asia Pacific region has many generic drug manufacturing companies that are already have significant presence in global retroviral drugs in market. Middle East and Africa region is expected to be key region owing to availability of large pool of patients with retroviral diseases. However, poor healthcare infrastructure and lack of awareness related to retroviral diseases among healthcare professionals expected to hamper market revenue growth in the region.

Some of the players in the antiretroviral drugs market are Abbott Laboratories (U.S.), AstraZeneca plc (U.K.), Modified Polymer Components, Inc. (Bristol-Myers-Squibb) (U.S), Gilead Sciences (U.S.), GlaxoSmithKline Plc (U.K.), and F. Hoffmann-La Roche AG (Switzerland) to name a few

In November 2016, ViiV Healthcare (Pfizer and GlaxoSmithKline's joint venture) received U.S. FDA approval to market selzentry for the treatment of CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents.

Report Outline:

+44 20 8123 2220
info@marketpublishers.com

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor’s overview, key findings and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup’s details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

+44 20 8123 2220
info@marketpublishers.com

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL ANTIRETROVIRAL DRUGS MARKET INTRODUCTION

2.1. Global Antiretroviral Drugs Market – Taxonomy
2.2. Global Antiretroviral Drugs Market –Definitions
  2.2.1. Drug Class
  2.2.2. Route of Administration
  2.2.3. Distribution Channel

3. GLOBAL ANTIRETROVIRAL DRUGS MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Antiretroviral Drugs Market Dynamics – Factors Impact Analysis
3.6. Global Antiretroviral Drugs Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Antiretroviral Drugs Market – Product Innovations

4. GLOBAL ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL ANTIRETROVIRAL DRUGS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

+44 20 8123 2220
info@marketpublishers.com

5.1.3. Market Opportunity Analysis
5.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3. Market Opportunity Analysis
5.3. Protease Inhibitors
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.3.3. Market Opportunity Analysis
5.4. Integrate Inhibitors
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.4.3. Market Opportunity Analysis
5.5. Fusion Inhibitors
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.5.3. Market Opportunity Analysis
5.6. Chemokine Receptor Inhibitors
5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.6.3. Market Opportunity Analysis
5.7. Others
5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.7.3. Market Opportunity Analysis

6. GLOBAL ANTIRETROVIRAL DRUGS MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Parenteral
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Oral
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis

7. GLOBAL ANTIRETROVIRAL DRUGS MARKET FORECAST, BY DISTRIBUTION

+44 20 8123 2220
info@marketpublishers.com

CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Retail Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.4.3. Market Opportunity Analysis

8. GLOBAL ANTIRETROVIRAL DRUGS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa

+44 20 8123 2220
info@marketpublishers.com

8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Class, Route of administration, Distribution Channel and Region, 2017 – 2023

9. NORTH AMERICA ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT's)
9.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
9.1.3. Protease Inhibitors
9.1.4. Integrate Inhibitors
9.1.5. Fusion Inhibitors
9.1.6. Chemokine Receptor Inhibitors
9.1.7. Others
9.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Parenteral
9.2.2. Oral
9.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Online Pharmacies
9.3.4. Others
9.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
9.6. North America Antiretroviral Drugs Market Dynamics – Trends

10. EUROPE ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

+44 20 8123 2220
info@marketpublishers.com

10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT's)
10.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
10.1.3. Protease Inhibitors
10.1.4. Integrate Inhibitors
10.1.5. Fusion Inhibitors
10.1.6. Chemokine Receptor Inhibitors
10.1.7. Others
10.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Parenteral
10.2.2. Oral
10.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Retail Pharmacies
10.3.2. Hospital Pharmacies
10.3.3. Online Pharmacies
10.3.4. Others
10.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
10.6. Europe Antiretroviral Drugs Market Dynamics – Trends

11. ASIA-PACIFIC ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT's)

+44 20 8123 2220
info@marketpublishers.com

11.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
11.1.3. Protease Inhibitors
11.1.4. Integrate Inhibitors
11.1.5. Fusion Inhibitors
11.1.6. Chemokine Receptor Inhibitors
11.1.7. Others
11.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Parenteral
11.2.2. Oral
11.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Retail Pharmacies
11.3.2. Hospital Pharmacies
11.3.3. Online Pharmacies
11.3.4. Others
11.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
11.6. Europe Antiretroviral Drugs Market Dynamics – Trends

12. LATIN AMERICA ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT's)
12.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
12.1.3. Protease Inhibitors
12.1.4. Integrate Inhibitors
12.1.5. Fusion Inhibitors

+44 20 8123 2220
info@marketpublishers.com

12.1.6. Chemokine Receptor Inhibitors
12.1.7. Others
12.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Parenteral
12.2.2. Oral
12.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Retail Pharmacies
12.3.2. Hospital Pharmacies
12.3.3. Online Pharmacies
12.3.4. Others
12.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
12.6. Latin America Antiretroviral Drugs Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
13.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
13.1.3. Protease Inhibitors
13.1.4. Integrate Inhibitors
13.1.5. Fusion Inhibitors
13.1.6. Chemokine Receptor Inhibitors
13.1.7. Others
13.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Parenteral
13.2.2. Oral

+44 20 8123 2220
info@marketpublishers.com

13.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Retail Pharmacies
13.3.2. Hospital Pharmacies
13.3.3. Online Pharmacies
13.3.4. Others
13.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Argentina
13.4.4. Venezuela
13.4.5. Rest of Latin America
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.5.1. Gulf Cooperation Council (GCC) Countries
13.5.2. Israel
13.5.3. South Africa
13.5.4. Rest of MEA
13.6. MEA Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
13.7. MEA Antiretroviral Drugs Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Abbott Laboratories (U.S.)
14.2.2. AstraZeneca plc (U.K.)
14.2.3. Modified Polymer Components, Inc. (Bristol-Myers-Squibb) (U.S)
14.2.4. Gilead Sciences (U.S.)
14.2.5. GlaxoSmithKline Plc (U.K.)
14.2.6. F. Hoffmann-La Roche AG (Switzerland)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global Antiretroviral Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Product link: https://marketpublishers.com/r/G4B4DDE645DEN.html

Price: US$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G4B4DDE645DEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com